Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company's primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway. Its product candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. The Company is developing AQX-1125 as a treatment in interstitial cystitis/bladder pain syndrome (IC/BPS), a chronic inflammatory disease of the bladder. AQX-1125 is a SHIP1 activator that has demonstrated preliminary safety, anti-inflammatory potential and drug properties in multiple preclinical studies.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:AQXP
- CUSIP: N/A
- Web: www.aqxpharma.com
Capitalization:- Market Cap: $322.63 million
- Outstanding Shares: 23,464,000
Average Prices:- 50 Day Moving Avg: $14.27
- 200 Day Moving Avg: $14.66
- 52 Week Range: $9.83 - $19.97
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -6.17
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $5.31 per share
- Price / Book: 2.59
Profitability:- Return on Equity: -29.54%
- Return on Assets: -27.88%
Debt:- Current Ratio: 16.28%
- Quick Ratio: 16.28%
Misc:- Average Volume: 68,069 shs.
- Beta: -16.98
- Short Ratio: 20.45
Frequently Asked Questions for Aquinox Pharmaceuticals (NASDAQ:AQXP)
What is Aquinox Pharmaceuticals' stock symbol?
Aquinox Pharmaceuticals trades on the NASDAQ under the ticker symbol "AQXP."
How were Aquinox Pharmaceuticals' earnings last quarter?
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.59) EPS for the quarter, meeting the consensus estimate of ($0.59). View Aquinox Pharmaceuticals' Earnings History.
When will Aquinox Pharmaceuticals make its next earnings announcement?
Where is Aquinox Pharmaceuticals' stock going? Where will Aquinox Pharmaceuticals' stock price be in 2017?
4 equities research analysts have issued 1-year target prices for Aquinox Pharmaceuticals' stock. Their forecasts range from $22.00 to $28.00. On average, they expect Aquinox Pharmaceuticals' stock price to reach $24.67 in the next year. View Analyst Ratings for Aquinox Pharmaceuticals.
Who are some of Aquinox Pharmaceuticals' key competitors?
Some companies that are related to Aquinox Pharmaceuticals include AMAG Pharmaceuticals (AMAG), SciClone Pharmaceuticals (SCLN), Corium International (CORI), Teligent (TLGT), Tetraphase Pharmaceuticals (TTPH), Aceto Corporation (ACET), Collegium Pharmaceutical (COLL), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Concordia International Corp. (CXRX), SCYNEXIS (SCYX) and Evoke Pharma (EVOK).
Who are Aquinox Pharmaceuticals' key executives?
Aquinox Pharmaceuticals' management team includes the folowing people:
- David J. Main, Co-Founder, President and Chief Executive Officer and Chairman of the Board
- Kamran Alam, Chief Financial Officer, Vice President - Finance
- Lloyd Mackenzie, Vice President - Technical Operations and Planning
- David Chilton Mitchell, Vice President - Global Regulatory Affairs & Quality Assurance
- Barbara Troupin M.D., Chief Medical Officer, Vice President - Clinical Development
- Robert E. Pelzer, Lead Independent Director
- Gary J. Bridger Ph.D., Director
- Daniel J. Levitt M.D., Ph.D., Director
- Richard S. Levy M.D., Director
- Kelvin M. Neu M.D., Director
Who owns Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (5.96%), Franklin Resources Inc. (5.64%), Goldman Sachs Group Inc. (4.11%), Vanguard Group Inc. (1.21%), Royce & Associates LP (0.62%) and Emory University (0.45%). Company insiders that own Aquinox Pharmaceuticals stock include Bros Advisors Lp Baker and David Main. View Institutional Ownership Trends for Aquinox Pharmaceuticals.
Who sold Aquinox Pharmaceuticals stock? Who is selling Aquinox Pharmaceuticals stock?
Who bought Aquinox Pharmaceuticals stock? Who is buying Aquinox Pharmaceuticals stock?
Aquinox Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Nexthera Capital LP, Sphera Funds Management LTD., Vanguard Group Inc., Archon Partners LLC, Bank of New York Mellon Corp, Northern Trust Corp and Alps Advisors Inc.. View Insider Buying and Selling for Aquinox Pharmaceuticals.
How do I buy Aquinox Pharmaceuticals stock?
Shares of Aquinox Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aquinox Pharmaceuticals' stock price today?
One share of Aquinox Pharmaceuticals stock can currently be purchased for approximately $13.75.
MarketBeat Community Rating for Aquinox Pharmaceuticals (NASDAQ AQXP)MarketBeat's community ratings are surveys of what our community members think about Aquinox Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Aquinox Pharmaceuticals (NASDAQ:AQXP)Earnings History by Quarter for Aquinox Pharmaceuticals (NASDAQ AQXP)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/7/2017 | | ($0.59) | | | | | N/A |  |
| 8/8/2017 | 6/30/2017 | ($0.59) | ($0.59) | | | View | Listen | |
| 5/9/2017 | 3/31/2017 | ($0.51) | ($0.36) | | | View | N/A | |
| 3/9/2017 | 12/31/2016 | ($0.51) | ($0.48) | | | View | Listen | |
| 11/9/2016 | Q316 | ($0.58) | ($0.46) | | | View | N/A | |
| 8/4/2016 | Q2 | ($0.41) | ($0.63) | | | View | N/A | |
| 5/10/2016 | Q1 | ($0.35) | ($0.39) | | | View | N/A | |
| 11/10/2015 | Q315 | ($0.45) | ($0.43) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.56) | ($0.44) | | | View | N/A | |
| 5/12/2015 | Q115 | ($0.83) | ($0.60) | | | View | N/A | |
| 4/15/2015 | | ($0.57) | ($0.78) | | | View | N/A | |
| 3/16/2015 | Q4 2014 | ($0.76) | ($0.78) | | | View | N/A | |
| 11/4/2014 | Q3 2014 | ($0.29) | ($0.59) | | | View | N/A | |
| 8/11/2014 | Q2 2014 | ($0.27) | ($0.51) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)2017 EPS Consensus Estimate: ($2.43)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.57) | ($0.57) | ($0.57) |
| Q2 2017 | 1 | ($0.59) | ($0.59) | ($0.59) |
| Q3 2017 | 1 | ($0.62) | ($0.62) | ($0.62) |
| Q4 2017 | 1 | ($0.65) | ($0.65) | ($0.65) |
(Data provided by Zacks Investment Research)
Dividend History for Aquinox Pharmaceuticals (NASDAQ:AQXP)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aquinox Pharmaceuticals (NASDAQ:AQXP)Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 95.15%
Insider Trades by Quarter for Aquinox Pharmaceuticals (NASDAQ:AQXP)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/5/2017 | David Main | Insider | Sell | 15,625 | $13.26 | $207,187.50 | |
| 1/9/2017 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 398,062 | $17.18 | $6,838,705.16 | |
| 9/20/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 2,783,605 | $12.25 | $34,099,161.25 | |
| 3/16/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 471,667 | $7.99 | $3,768,619.33 | |
| 3/15/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 109,912 | $7.98 | $877,097.76 | |
| 1/26/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 140,786 | $10.80 | $1,520,488.80 | |
| 1/20/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 112,034 | $9.48 | $1,062,082.32 | |
| 1/19/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 78,045 | $9.11 | $710,989.95 | |
| 1/15/2016 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 202,623 | $8.28 | $1,677,718.44 | |
| 9/10/2015 | Bros. Advisors Lp Baker | Major Shareholder | Buy | 2,480,032 | $15.50 | $38,440,496.00 | |
| 8/24/2015 | David Chilton Mitchell | VP | Buy | 3,575 | $17.81 | $63,670.75 | |
| 8/12/2015 | Kamran Alam | CFO | Sell | 29,079 | $18.67 | $542,904.93 | |
| 8/12/2015 | Lloyd Mackenzie | VP | Sell | 35,887 | $18.67 | $670,010.29 | |
| 12/17/2014 | & Johnson Johnson | Major Shareholder | Sell | 8,100 | $7.62 | $61,722.00 | |
| 12/12/2014 | & Johnson Johnson | Major Shareholder | Sell | 5,000 | $7.51 | $37,550.00 | |
| 12/10/2014 | & Johnson Johnson | Major Shareholder | Sell | 8,300 | $7.72 | $64,076.00 | |
| 12/9/2014 | & Johnson Johnson | Major Shareholder | Sell | 5,000 | $7.73 | $38,650.00 | |
| 12/8/2014 | & Johnson Johnson | Major Shareholder | Sell | 2,000 | $7.69 | $15,380.00 | |
| 12/5/2014 | & Johnson Johnson | Major Shareholder | Sell | 15,900 | $7.76 | $123,384.00 | |
| 12/1/2014 | & Johnson Johnson | Major Shareholder | Sell | 1,200 | $7.54 | $9,048.00 | |
| 11/26/2014 | & Johnson Johnson | Major Shareholder | Sell | 2,000 | $7.75 | $15,500.00 | |
| 11/24/2014 | & Johnson Johnson | Major Shareholder | Sell | 9,500 | $8.14 | $77,330.00 | |
| 3/12/2014 | Pfizer Inc | Major Shareholder | Buy | 272,727 | $11.00 | $2,999,997.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Aquinox Pharmaceuticals (NASDAQ:AQXP)
Latest Headlines for Aquinox Pharmaceuticals (NASDAQ:AQXP)
| Source: |
|
| Date | Headline |
|---|
 | Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 18 at 4:25 PM |
 | Reviewing Aquinox Pharmaceuticals (AQXP) & Its Peers
www.americanbankingnews.com - September 18 at 4:28 AM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 16 at 4:54 PM |
| ValuEngine Lowers Aquinox Pharmaceuticals, Inc. (AQXP) to Sell
www.americanbankingnews.com - September 15 at 11:12 PM |
 | Aquinox Pharmaceuticals: Buy, Sell Or Hold? - Seeking Alpha
seekingalpha.com - September 1 at 9:35 PM |
 | Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome - GlobeNewswire (press release)
globenewswire.com - August 29 at 9:24 PM |
 | Aquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
www.streetinsider.com - August 29 at 2:07 AM |
| Collegium Pharmaceutical (COLL) and Aquinox Pharmaceuticals (AQXP) Head-To-Head Comparison
www.americanbankingnews.com - August 29 at 12:22 AM |
| Aquinox Pharma (AQXP) Issues Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder ... - StreetInsider.com
www.streetinsider.com - August 28 at 9:07 PM |
 | Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
feeds.benzinga.com - August 28 at 9:46 AM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - August 23 at 12:20 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 22 at 4:36 PM |
| Dr. Reddy's Laboratories (RDY) versus Aquinox Pharmaceuticals (AQXP) Head-To-Head Contrast
www.americanbankingnews.com - August 22 at 4:16 PM |
 | Analyzing the Financial Health of Biotech Companies - PR Newswire (press release)
www.prnewswire.com - August 17 at 10:27 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - August 15 at 4:52 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - August 10 at 4:32 PM |
| FY2017 EPS Estimates for Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Increased by Analyst
www.americanbankingnews.com - August 10 at 1:50 PM |
| Aquinox Pharmaceuticals' (AQXP) CEO David Main on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 3:52 PM |
| Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - August 8 at 3:52 PM |
| Investor Network: Aquinox Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 3:52 PM |
| Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 3:51 PM |
| Aquinox reports 2Q loss
finance.yahoo.com - August 8 at 3:51 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Issues Earnings Results
www.americanbankingnews.com - August 8 at 2:24 PM |
| Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - August 6 at 1:56 PM |
| Zacks: Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (AQXP) to Post -$0.59 EPS
www.americanbankingnews.com - August 5 at 7:08 AM |
| Aquinox to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 2 at 4:50 PM |
| Aquinox to Present at Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 2 at 4:50 PM |
| Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - August 1 at 4:59 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Cut to "Sell" at BidaskClub
www.americanbankingnews.com - July 29 at 9:21 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 4:39 PM |
| Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) to Release Earnings on Wednesday
www.americanbankingnews.com - July 26 at 7:20 AM |
| Analyzing Aquinox Pharmaceuticals (AQXP) and Teligent (TLGT)
www.americanbankingnews.com - July 19 at 8:51 AM |
| Brokerages Anticipate Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - July 13 at 10:20 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - July 11 at 5:26 PM |
| Corium International (CORI) Catches Eye: Stock Jumps 11.9%
finance.yahoo.com - July 8 at 6:21 AM |
| Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 4:58 PM |
| Contrasting Theravance Biopharma (TBPH) and Aquinox Pharmaceuticals (AQXP)
www.americanbankingnews.com - June 26 at 2:26 PM |
| Brokerages Expect Aquinox Pharmaceuticals, Inc. (AQXP) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - June 19 at 10:28 PM |
| Aquinox Pharmaceuticals, Inc. (AQXP) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - June 13 at 1:00 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 6 at 2:38 PM |
| Insider Selling: Aquinox Pharmaceuticals Inc (AQXP) Insider Sells 15,625 Shares of Stock
www.americanbankingnews.com - June 5 at 8:07 PM |
| Supernus Pharmaceuticals (SUPN) Jumps: Stock Rises 6.2%
finance.yahoo.com - June 1 at 3:50 PM |
| Aquinox to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - June 1 at 3:50 PM |
| Aquinox Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.24) Per Share (AQXP)
www.americanbankingnews.com - May 15 at 8:54 AM |
| Short Interest in Aquinox Pharmaceuticals Inc (AQXP) Declines By 19.6%
www.americanbankingnews.com - May 14 at 9:14 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 12 at 2:38 PM |
| Aquinox Pharmaceuticals Inc (AQXP) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 11 at 10:52 PM |
 | BRIEF-Aquinox Pharmaceuticals Qtrly loss per share $0.36
www.reuters.com - May 11 at 3:59 PM |
| Research Analysts Issue Forecasts for Aquinox Pharmaceuticals Inc's FY2017 Earnings (AQXP)
www.americanbankingnews.com - May 11 at 11:42 AM |
| Aquinox Pharmaceuticals Inc (AQXP) Given a $28.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 11:36 PM |
Aquinox Pharmaceuticals (AQXP) Chart for Sunday, September, 24, 2017
